Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Policy Panic Persists; Subpoena Demands Vex Valeant

This article was originally published in Scrip

Executive Summary

Even as Wall Street analysts were trying to calm biotech investors on Sept. 28 after last week's panic over concerns Washington would try to control prices – triggered by the news that Turing Pharmaceuticals had increased by more than 5,000% the cost of its toxoplasmosis medicine Daraprim (pyrimethamine) – Democrats were turning up the heat, taking aim at Valeant Pharmaceuticals.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts